TACE联合阿帕替尼对晚期肝癌的临床疗效

Clinical effect of TACE combined with apatinib on advanced liver cancer

目的探讨肝动脉灌注化疗栓塞术(transcatheter arterial chemoembolization,TACE)联合阿帕替尼治疗晚期肝癌的临床疗效与单独TACE治疗晚期肝癌患者的临床疗效的差异。方法选择2016年3月~2017年3月我院收治的晚期肝癌患者50例,将其随机分为实验组和对照组,每组25例。其中,实验组进行TACE联合口服阿帕替尼治疗,对照组只进行TACE治疗。30 d为1个疗程,两组患者共同治疗3个疗程。比较两组的治疗效果、生活质量、肝功能及不良反应情况。结果实验组的客观缓解率(88%)明显高于对照组(48%)(P<0.05);躯体功能、心理功能、症状/副作用、社会功能及生活质量总得分均高于对照组(P<0.05);谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBil)水平均低于对照组(P<0.05);且发热、恶心、呕吐等不良反应发生率均小于对照组(P<0.05)。结论TACE联合口服阿帕替尼对肝癌患者的治疗率有所提高,同时晚期肝癌患者的生活质量和肝功能状况也所有改善,此外副作用也降低。

Objective To explore the difference between the clinical efficacy of transcatheter arterial chemoembolization（TACE） combined with apatinib and that of TACE alone in patients with advanced hepatocellular carcinoma.Methods A total of 50 patients with advanced hepatocellular carcinoma admitted inour hospital from March 2016 to March 2017 were selected and randomly divided into the experimental group and the control group,with 25 cases in each group.Among them,the experimental group was treated with TACE combined with oral apatinib,and the control group was treated with TACE only.30 days was a course of treatment.Two groups of patients were treated with 3 courses.The treatment effect,quality of life,liver function and adverse reactions of the two groups were compared.Results The objective remission rate in the experimental group（88%） was significantly higher than that in the control group（48%）（P〈0.05）;the total scores of physical function,psychological function,symptoms/side effects,social function and quality of life in the experimental group were all higher than those in the control group（P〈0.05）.Aspartate aminotransferase（AST）,Alanine aminotransferase（ALT）,total bilirubin（TBil） levels in the experimental group were lower than those of the control group（P〈0.05）.And the incidence of adverse reactions such as fever,nausea,vomiting was lower than that of the control group（P〈0.05）.Conclusion The therapeutic rate of TACE combined with oral apatinib in patients with liver cancer has been improved.At the same time,the quality of life and liver function of patients with advanced liver cancer have also been improved,and the side effects have also been reduced.